Doctored by Charles Piller

Doctored

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's

Charles Piller

Atria/One Signal Publishers · Print & ebook · February 4, 2025

An Economist Best Book of 2025 So Far For readers of Empire of Pain and Dopesick, a “gripping story of medical groupthink and warped incentives” (The Economist) that follows how Alzheimer’s disease treatment has been set back by corrupt researchers, negligent regulators, and the profit motives of Big Pharma.

We earn from qualifying purchases.

Who it’s for
A hard look at how ambition and medicine tangle, with a steady, unsentimental eye.
Genres
Alzheimer's & Dementia, Pharma & Biotech Industry, Health Policy
Published
Atria/One Signal Publishers, February 4, 2025

Nearest books

Matched by what the books are about, then ordered by what their readers also loved. Most of these share its genre: Pharma & Biotech Industry.

  1. No More TearsGardiner Harris57% match
  2. Follow the ScienceSharyl Attkisson66% match
  3. False ClaimsLisa Pratta67% match
  4. UnshrunkLaura Delano57% match

For younger readers: Big Lies

Start with three books, and this one can be the first.

Members get a new edition every morning: a route out from their books to essays, research and talks, with the reason for each.

Start with this book

About this book

An Economist Best Book of 2025 So Far For readers of Empire of Pain and Dopesick, a “gripping story of medical groupthink and warped incentives” (The Economist) that follows how Alzheimer’s disease treatment has been set back by corrupt researchers, negligent regulators, and the profit motives of Big Pharma. Nearly seven million Americans live with Alzheimer’s disease, a tragedy that is already projected to grow into a $1 trillion crisis by 2050.

Continue reading

While families suffer and promises of pharmaceutical breakthroughs keep coming up short, investigative journalist Charles Piller’s Doctored shows that we’ve quite likely been walking the wrong path to finding a cure all along—led astray by a cabal of self-interested researchers, government accomplices, and corporate greed. In this “riveting must-read master class in science journalism” (Gary Taubes, author of Rethinking Diabetes), Piller begins with a whistleblower—Vanderbilt professor Matthew Schrag—whose work exposed a massive scandal. Schrag found that a University of Minnesota lab led by a precocious young scientist and a Nobel Prize–rumored director delivered apparently falsified data at the heart of the leading hypothesis about the disease. Piller uncovers evidence that hundreds of important Alzheimer’s research papers are based on false data. In the process, he reveals how even against a flood of money and influence, a determined cadre of scientific renegades have fought back to challenge the field’s institutional powers in service to science and the tens of thousands of patients who have been drawn into trials to test dubious drugs. Piller “masterfully unfolds an epic tale of astounding fraud, scientific egos run amok, and steely heroism in the pursuit of truth, creating both a page-turner and a seminal account of deceit that will long be remembered alongside Theranos and Enron as a scandal for the ages” (Katherine Eban, author of Bottle of Lies).

Why It Hooks

A hard look at how ambition and medicine tangle, with a steady, unsentimental eye.

Come here for

  • science explanation with a sharper edge
  • industry, error, and consequence

Expect

  • clear-eyed reporting
  • clinical, uneasy tension

Where it sits

Alzheimer's & Dementia63%
Pharma & Biotech Industry38%
Health Policy27%

Percentages are BookFrontier’s reading of the book.

Publisher categories

  • Pharma & Biotech Industry
  • Neuroscience
  • Pharmaceutical Technology
Authors
Charles Piller
Publisher
Atria/One Signal Publishers
Published
February 4, 2025
Format
Print & ebook
Reading lane
Pharma & Biotech Industry